MDxHealth (MDXH)
Market Price (3/30/2026): $2.21 | Market Cap: $110.6 MilSector: Health Care | Industry: Life Sciences Tools & Services
MDxHealth (MDXH)
Market Price (3/30/2026): $2.21Market Cap: $110.6 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -52% | Weak multi-year price returns2Y Excs Rtn is -27% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.8% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% | ||
| Key risksMDXH key risks include [1] securing and maintaining adequate reimbursement and payer acceptance for its products, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -52% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -27% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% |
| Key risksMDXH key risks include [1] securing and maintaining adequate reimbursement and payer acceptance for its products, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MDxHealth (MDXH) stock has lost about 35% since 11/30/2025 because of the following key factors:
1. Q4 2025 Earnings Miss and Increased Net Loss. MDxHealth reported its Q4 2025 earnings on February 26, 2026, announcing an Earnings Per Share (EPS) of -$0.17, which missed the consensus estimate of -$0.13 by $0.04, a 30.77% surprise to the downside. The company also reported a net loss of $8.9 million for the quarter, an increase from $6.8 million in the prior year period, primarily attributed to increased operating expenses.
2. Persistent Operating Losses and Declining Gross Margins. Despite reporting revenue growth, MDxHealth continued to face profitability challenges. For the full year 2025, the company's gross margins decreased to 61.2%, falling short of its forecasted 65.5%. Additionally, the company recorded an operating loss of $5.26 million for Q4 2025 and a negative net margin of 31.07%, indicating ongoing financial headwinds.
Show more
1. Q4 2025 Earnings Miss and Increased Net Loss. MDxHealth reported its Q4 2025 earnings on February 26, 2026, announcing an Earnings Per Share (EPS) of -$0.17, which missed the consensus estimate of -$0.13 by $0.04, a 30.77% surprise to the downside. The company also reported a net loss of $8.9 million for the quarter, an increase from $6.8 million in the prior year period, primarily attributed to increased operating expenses.
2. Persistent Operating Losses and Declining Gross Margins. Despite reporting revenue growth, MDxHealth continued to face profitability challenges. For the full year 2025, the company's gross margins decreased to 61.2%, falling short of its forecasted 65.5%. Additionally, the company recorded an operating loss of $5.26 million for Q4 2025 and a negative net margin of 31.07%, indicating ongoing financial headwinds.
Show more
Stock Movement Drivers
Fundamental Drivers
The -33.9% change in MDXH stock from 11/30/2025 to 3/29/2026 was primarily driven by a -33.9% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.69 | 2.44 | -33.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 103 | 103 | 0.0% |
| P/S Multiple | 1.8 | 1.2 | -33.9% |
| Shares Outstanding (Mil) | 50 | 50 | 0.0% |
| Cumulative Contribution | -33.9% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MDXH | -33.9% | |
| Market (SPY) | -5.3% | 49.9% |
| Sector (XLV) | -8.7% | 25.9% |
Fundamental Drivers
The -31.3% change in MDXH stock from 8/31/2025 to 3/29/2026 was primarily driven by a -36.5% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.55 | 2.44 | -31.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 99 | 103 | 4.2% |
| P/S Multiple | 1.9 | 1.2 | -36.5% |
| Shares Outstanding (Mil) | 52 | 50 | 3.9% |
| Cumulative Contribution | -31.3% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MDXH | -31.3% | |
| Market (SPY) | 0.6% | 49.6% |
| Sector (XLV) | 5.2% | 25.1% |
Fundamental Drivers
The 34.1% change in MDXH stock from 2/28/2025 to 3/29/2026 was primarily driven by a 21.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.82 | 2.44 | 34.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 85 | 103 | 21.7% |
| P/S Multiple | 1.0 | 1.2 | 16.6% |
| Shares Outstanding (Mil) | 47 | 50 | -5.5% |
| Cumulative Contribution | 34.1% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MDXH | 34.1% | |
| Market (SPY) | 9.8% | 25.7% |
| Sector (XLV) | -2.1% | 15.6% |
Fundamental Drivers
The 2439900.0% change in MDXH stock from 2/28/2023 to 3/29/2026 was primarily driven by a 2118884.9% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.00 | 2.44 | 2439900.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 103 | 241.6% |
| P/S Multiple | 0.0 | 1.2 | 2118884.9% |
| Shares Outstanding (Mil) | 17 | 50 | -66.3% |
| Cumulative Contribution | 2439900.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MDXH | 2439900.0% | |
| Market (SPY) | 69.4% | 0.6% |
| Sector (XLV) | 18.4% | -2.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDXH Return | 3% | -100% | 3939900% | -40% | 51% | -24% | 167% |
| Peers Return | 4% | -15% | -8% | -24% | 39% | -44% | -52% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| MDXH Win Rate | 33% | 9% | 33% | 42% | 58% | 0% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 42% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| MDXH Max Drawdown | 0% | -100% | 0% | -60% | -41% | -24% | |
| Peers Max Drawdown | -20% | -41% | -42% | -35% | -16% | -50% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, AIDX, POAS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | MDXH | S&P 500 |
|---|---|---|
| 2018 Correction | ||
| % Loss | -83.7% | -19.8% |
| % Gain to Breakeven | 515.0% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to A, ATEC, CERS, AIDX, POAS
In The Past
MDxHealth's stock fell -83.7% during the 2018 Correction from a high on 3/13/2017. A -83.7% loss requires a 515.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MDxHealth (MDXH)
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
MDxHealth (MDXH) is a molecular diagnostics company focused on prostate cancer. It sells its diagnostic tests to healthcare providers who order them for patients. Therefore, MDxHealth primarily sells to other companies rather than directly to individuals. MDxHealth's major customers are typically a diffuse base of healthcare entities rather than a few single, large publicly traded companies. Given this, the categories of customers are:- Urology Practices and Clinics: These are the primary healthcare providers, including individual urologists and group practices, who order MDxHealth's diagnostic tests (such as SelectMDx and ConfirmMDx) for their patients.
- Hospitals and Healthcare Systems: Larger medical institutions and integrated delivery networks that include urology departments also utilize and order MDxHealth's tests.
- Healthcare Distributors: In certain international markets, MDxHealth partners with third-party distributors who then sell and facilitate the use of their diagnostic tests to local healthcare providers.
AI Analysis | Feedback
- Thermo Fisher Scientific Inc. (TMO)
- QIAGEN N.V. (QGEN)
- Roche Diagnostics GmbH (ROG)
- Promega Corporation
AI Analysis | Feedback
Michael K. McGarrity, Chief Executive Officer
Mr. McGarrity was appointed CEO in February 2019. He possesses over 25 years of experience in the healthcare industry, encompassing device, diagnostics, and biotechnology. Prior to joining MDxHealth, he served as CEO of Sterilis Medical. Before Sterilis, Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he successfully orchestrated an operational and strategic turnaround that led to its sale to Luminex (NASDAQ: LMNX) in 2016. He also spent 13 years at Stryker Corporation (NYSE: SYK) in various leadership roles within sales, marketing, and executive general management.
Scott McMahan, Interim Chief Financial Officer
Mr. McMahan assumed the role of Interim Chief Financial Officer at MDxHealth on July 30, 2025, following the resignation of the previous CFO. Prior to this, he served as the Vice President of Finance and Accounting for MDxHealth.
John Bellano, Chief Commercial Officer
Mr. Bellano joined MDxHealth in June 2019 and brings over 25 years of experience in the healthcare industry, with a focus on molecular diagnostics for the past two decades. His previous roles include Chief Commercial Officer at Sterilis, LLC, and commercial leadership positions at pharmacogenomic companies such as Assurex Health (Myriad Genetics) and AltheaDx. He has also held senior leadership roles at GenMark Diagnostics and was Vice President of Global Sales at Nanosphere.
Joseph Sollee, Executive Vice President of Corporate Development & General Counsel
Mr. Sollee has more than 20 years of experience in the healthcare industry, with senior management roles in private and publicly listed pharmaceuticals, health information technology, and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Before MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&L Gates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. His background also includes practicing as a corporate attorney at Swidler & Berlin and as an investment banker at Smith Barney.
Kim Leroux, Executive Vice President, Revenue Cycle Management
Ms. Leroux has over 20 years of leadership experience in healthcare diagnostics, with extensive expertise in revenue cycle management, managed care, and payer relations. At MDxHealth, she is responsible for leading the strategy and execution to optimize financial performance and expand patient access to precision diagnostics.
AI Analysis | Feedback
Key Risks to MDxHealth (MDXH)
- Financial Health and Profitability: MDxHealth faces significant financial risks, characterized by poor financial strength, high debt levels, and an Altman Z-Score indicating a potential for financial instability. The company has reported ongoing net losses, with its Q4 2025 net loss increasing to $8.9 million. Concerns exist regarding its ability to achieve profitability targets, as these are not consistently reflected in most analyst models. Additionally, the company's term loan agreements contain restrictions that could limit operational flexibility, and a failure to comply with financial covenants could lead to lenders accelerating debt payments or foreclosing on assets.
- Reimbursement and Coverage for Tests: A critical risk for MDxHealth, as a diagnostics company, is the uncertainty surrounding the coverage and adequate reimbursement of its current and future tests by third-party payers, including health insurance companies. The commercial success and widespread adoption of MDxHealth's products are heavily dependent on favorable reimbursement policies and the willingness of payers to cover its services. Changes in payer claims reimbursement practices or difficulty in securing adequate coverage could materially impact the company's revenue and financial performance.
- Intense Competition and Rapid Technological Changes: The molecular diagnostics industry, in which MDxHealth operates, is highly competitive and subject to rapid technological advancements. The company faces the ongoing challenge of keeping pace with competitors and ensuring its diagnostic tests remain at the forefront of innovation. Failure to continually develop new products, maintain a competitive edge, or adapt to evolving technologies could result in a loss of market share and hinder its ability to grow and sustain its business.
AI Analysis | Feedback
null
AI Analysis | Feedback
MDxHealth (symbol: MDXH) operates in the precision diagnostics market, primarily focusing on urologic cancers and infections. The company has identified significant addressable markets for its main products and services, predominantly within the U.S. region.
- The aggregate total addressable market (TAM) for MDxHealth's comprehensive portfolio of precision diagnostics, which targets all stages of prostate cancer and advanced UTI detection, is estimated to be approximately $4.9 billion.
- For SelectMDx, a non-invasive liquid biopsy test for prostate cancer, the addressable market is estimated at $1.5 billion. This market size is for the U.S.
- The Genomic Prostate Score (GPS) test, used for treatment planning in prostate cancer, targets a market of $450 million.
- ResolveMDx, an advanced diagnostic tool for urinary tract infections (UTIs), addresses a U.S. market of approximately $1.0 billion, representing about 2 million tests annually.
- For MonitorMDx, a non-invasive test currently in development for active surveillance of localized prostate cancer, the estimated addressable market could be $450 million in the U.S., accounting for approximately 1.5 million men annually.
- While no specific dollar market size is provided for ConfirmMDx, it is a flagship epigenetic assay for prostate cancer detection post-biopsy.
- For AssureMDx for Bladder Cancer, launched in the United States, there are approximately 11 million patients annually referred to a urologist for hematuria, a common symptom of bladder cancer, indicating a substantial patient population for this test.
AI Analysis | Feedback
MDxHealth (MDXH) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:
- Successful Integration and Synergies from the ExoDx Acquisition: The recent acquisition of ExoDx is a significant growth catalyst. MDxHealth anticipates ExoDx to contribute more than $20 million in revenue in 2026. This integration involves cross-selling opportunities within the expanded customer base and aligning sales teams, which is expected to enhance their position in the prostate cancer diagnostic market and expand their overall diagnostic menu.
- Continued Growth in Liquid-Based Testing Volumes: MDxHealth has demonstrated substantial growth in its liquid-based test volumes, which include products like SelectMDx, ResolveMDx, and the newly acquired ExoDx. In the fourth quarter of 2025, liquid-based test volumes increased by 128% year-over-year, indicating a strong and ongoing demand for these diagnostic solutions.
- Expansion of Diagnostic Menu and Service Offerings to Urology Clients: The company emphasizes a strategy of "menu expansion" across both tissue and liquid biopsy products, which broadens their diagnostic capabilities within the prostate cancer pathway. This expansion, coupled with robust sales channels and expanded service offerings to urology clients, is credited as a key driver for sustained growth.
- Strengthening Market Position in Urology Cancer Diagnostics: MDxHealth aims to solidify its standing in the prostate cancer pathway and leverage the inherent growth of its target end markets. Specializing in molecular diagnostic tests for prostate cancer and other urologic diseases positions the company to capitalize on the increasing need for precision diagnostics in this sector.
AI Analysis | Feedback
Capital Allocation Decisions for MDxHealth (MDXH)
Share Issuance
- MDxHealth has been listed on NASDAQ since 2021, indicating share issuances related to its public listing.
- The number of outstanding shares significantly increased from 16.87 million in 2022 to 50.06 million in February 2026.
- The company issues stock options to employees, directors, and consultants.
Inbound Investments
- On February 3, 2023, MVM Partners, LLC made a significant BUY transaction in MDxHealth SA valued at $4,000,000.
- Earlier insider trading activity in January 2021 and September 2020 also showed BUY transactions.
- Institutional investors such as AWM Investment Company, Inc., MVM Partners, LLC, and others hold significant positions in MDxHealth.
Outbound Investments
- MDxHealth entered into a definitive agreement on August 5, 2025, to acquire the ExoDx business from Bio-Techne Corporation for a total consideration of $15 million.
- The acquisition involved an initial payment of $5 million in stock at closing, with an additional $2.5 million to be paid annually over the subsequent four years, split evenly between cash and cash or stock at MDxHealth's discretion.
- This acquisition, which includes the ExoDx Prostate test and a CLIA-certified clinical laboratory, was expected to close in September 2025 and is anticipated to accelerate revenue growth and be accretive to adjusted EBITDA.
Capital Expenditures
- Capital expenditures in the most recent reported quarter totaled -$0.263 million USD.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is MDxHealth Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MDXH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.12 |
| Mkt Cap | 1.0 |
| Rev LTM | 485 |
| Op Inc LTM | -11 |
| FCF LTM | -2 |
| FCF 3Y Avg | -17 |
| CFO LTM | 25 |
| CFO 3Y Avg | -13 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 18.0% |
| Rev Chg 3Y Avg | 19.2% |
| Rev Chg Q | 15.7% |
| QoQ Delta Rev Chg LTM | 3.8% |
| Op Mgn LTM | -5.9% |
| Op Mgn 3Y Avg | -14.6% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 4.1% |
| CFO/Rev 3Y Avg | -6.1% |
| FCF/Rev LTM | -0.0% |
| FCF/Rev 3Y Avg | -13.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 1.9 |
| P/EBIT | -11.7 |
| P/E | -7.7 |
| P/CFO | 29.6 |
| Total Yield | -6.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.6% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -24.0% |
| 3M Rtn | -38.2% |
| 6M Rtn | -37.3% |
| 12M Rtn | 1.2% |
| 3Y Rtn | -33.7% |
| 1M Excs Rtn | -18.8% |
| 3M Excs Rtn | -30.4% |
| 6M Excs Rtn | -32.5% |
| 12M Excs Rtn | -11.8% |
| 3Y Excs Rtn | -94.5% |
Price Behavior
Price Behavior
| Market Price | $2.44 | |
| Market Cap ($ Bil) | 0.1 | |
| Distance from 52W High | -51.2% | |
| 50 Days | 200 Days | |
| DMA Price | $3.44 | $3.40 |
| DMA Trend | up | down |
| Distance from DMA | -29.1% | -28.2% |
| 3M | 1YR | |
| Volatility | 58.9% | 59.7% |
| Downside Capture | 1.62 | 1.15 |
| Upside Capture | 151.61 | 186.83 |
| Correlation (SPY) | 48.5% | 26.3% |
MDXH Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.91 | 2.03 | 2.38 | 2.56 | 0.70 | 138.96 |
| Up Beta | 0.81 | 3.02 | 3.01 | 3.50 | 0.19 | -446.19 |
| Down Beta | 0.85 | 3.00 | 2.72 | 1.80 | 0.46 | 3.93 |
| Up Capture | 234% | 135% | 184% | 304% | 235% | 129971% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 17 | 24 | 54 | 115 | 255 |
| Down Capture | 264% | 115% | 211% | 225% | 113% | -96% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 24 | 36 | 66 | 125 | 278 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | 67.1% | 59.7% | 1.09 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 16.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 26.0% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 4.1% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -3.3% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 20.4% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 25.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | -3.4% | 62.0% | 0.12 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 9.5% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 19.3% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 6.5% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 1.7% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 13.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | -4.5% | 67.6% | 0.01 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 11.9% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 21.3% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 5.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 3.3% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 13.9% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 6-K |
| 06/30/2025 | 08/14/2025 | 6-K |
| 03/31/2025 | 05/14/2025 | 6-K |
| 12/31/2024 | 03/31/2025 | 20-F |
| 09/30/2024 | 11/06/2024 | 6-K |
| 06/30/2024 | 08/21/2024 | 6-K |
| 03/31/2024 | 05/01/2024 | 6-K |
| 12/31/2023 | 04/30/2024 | 20-F |
| 09/30/2023 | 11/08/2023 | 6-K |
| 06/30/2023 | 08/23/2023 | 6-K |
| 03/31/2023 | 05/15/2023 | 6-K |
| 12/31/2022 | 04/25/2023 | 20-F |
| 09/30/2022 | 01/20/2023 | 6-K |
| 06/30/2022 | 08/26/2022 | 6-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.